# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Richard Roundtree (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML015-SYN
- Date: 2026-09-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Leon Carrington, MD
- Calendar frame: modern shifted

## What we are working on

- Found a small, painless lump under the left nipple in the shower a few days ago; at first put it down to the breast enlargement he had at 13 **S**
- Embarrassed to bring up a breast lump and did not think a man could have breast cancer; worried that a diagnosis could cost him work and wants it kept private **S**

## Your goals

- Tissue diagnosis within one week of presentation. Target: 2026-10-05. Recorded outcome: Imaging and core biopsy the day after presentation; diagnosis explained on the sixth day. **S**
- Curative surgery within two weeks of diagnosis, with lymphedema prevention taught. Target: 2026-10-20. Recorded outcome: Mastectomy and axillary dissection two days after the diagnosis; clear margins; arm exercises and risk reduction taught. **S**
- Complete germline genetic testing with counseling before chemotherapy starts. Target: 2026-10-27. Recorded outcome: Panel sent on the day of diagnosis; result not yet back at the end of the episode. **S**
- Be ready to start adjuvant chemotherapy within six weeks of surgery: echocardiogram, hepatitis B screening, vaccines, and dental review done. Target: 2026-10-27. Recorded outcome: Echocardiogram normal; vaccines and hepatitis B screening at the preventive visit; dental review booked; first cycle scheduled. **S**

## What we agreed to do

- Urgent surgical oncology (breast) consultation for a suspected breast cancer with an abnormal left axillary node, core biopsy pending, to plan the operation and the axilla. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025) **S**
- Same-week diagnostic mammography and ultrasound of both breasts and both axillae, and ultrasound-guided core biopsy of the mass and the abnormal node with ER, PR, and HER2 testing. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025) **S**
- Genetic counseling and germline multigene panel testing (including BRCA2, BRCA1, PALB2, CHEK2, and ATM), as for every man with breast cancer, with a letter for relatives if a variant is found. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); Bedrosian I, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024;42(5):584-604 (2024) **S**
- Mastectomy with axillary lymph node dissection, then shoulder exercises and lymphedema risk reduction with arm measurements at each visit. Guideline: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025); Runowicz CD, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016) **S**
- Adjuvant chemotherapy given by medical oncology (doxorubicin and cyclophosphamide every three weeks for four cycles, then weekly paclitaxel for twelve weeks, about six months), after a baseline echocardiogram, hepatitis B screening, vaccines, and a dental review; radiation oncology review of post-mastectomy radiation after chemotherapy. Guideline: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025); Armenian SH, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: ASCO Clinical Practice Guideline. J Clin Oncol 2017;35(8):893-911 (2017); Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020 (2020) **S**
- Tamoxifen after chemotherapy for at least five years, the first-choice endocrine therapy for men, with venous thromboembolism, mood, hot flash, sexual side effect, and adherence checks at every visit. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Distress screening at each visit, plain information that men get breast cancer, confidential handling of his diagnosis at work, and the offer of a peer-support group for men with breast cancer. Guideline: Runowicz CD, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**

## Follow-up

- 2026-09-29: New painless lump under the left nipple in a man of 51 **S**
- 2026-10-05: Biopsy results: breast cancer; surgical oncology consultation; germline test and preparation for surgery **S**
- 2026-10-20: Review two weeks after mastectomy and axillary dissection: pathology, wound and arm care, and preparation for chemotherapy **S**
- 2026-10-27: Periodic adult preventive visit before chemotherapy **S**

This teaching document does not replace care from a qualified clinician.
